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Neuronal plasticity and neurotrophic factors in drug responses
E Castrén and H Antila
Neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and other members of the neurotrophin family, are
central mediators of the activity-dependent plasticity through which environmental experiences, such as sensory information are
translated into the structure and function of neuronal networks. Synthesis, release and action of BDNF is regulated by neuronal
activity and BDNF in turn leads to trophic effects such as formation, stabilization and potentiation of synapses through its
high-affinity TrkB receptors. Several clinically available drugs activate neurotrophin signaling and neuronal plasticity. In particular,
antidepressant drugs rapidly activate TrkB signaling and gradually increase BDNF expression, and the behavioral effects of
antidepressants are mediated by and dependent on BDNF signaling through TrkB at least in rodents. These findings indicate that
antidepressants, widely used drugs, effectively act as TrkB activators. They further imply that neuronal plasticity is a central
mechanism in the action of antidepressant drugs. Indeed, it was recently discovered that antidepressants reactivate a state of
plasticity in the adult cerebral cortex that closely resembles the enhanced plasticity normally observed during postnatal critical
periods. This state of induced plasticity, known as iPlasticity, allows environmental stimuli to beneficially reorganize networks
abnormally wired during early life. iPlasticity has been observed in cortical as well as subcortical networks and is induced by several
pharmacological and non-pharmacological treatments. iPlasticity is a new pharmacological principle where drug treatment
and rehabilitation cooperate; the drug acts permissively to enhance plasticity and rehabilitation provides activity to guide the
appropriate wiring of the plastic network. Optimization of iPlastic drug treatment with novel means of rehabilitation may help
improve the efficacy of available drug treatments and expand the use of currently existing drugs into new indications.
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INTRODUCTION
Neuronal plasticity is a process through which external and
internal environment of an individual gradually becomes repre-
sented in neuronal structure and function during development
and through learning. Although gross connectivity develops
through genetically governed guidance, fine-tuning takes place
through experience and activity-dependent plasticity, where
neurons and connections that actively participate in network
function are selected for stabilization and strengthened, whereas
inactive contacts are weakened or eliminated.1–3
Neuronal plasticity does not only involve trophic processes such
as neurogenesis and synaptogenesis but also includes atrophic
processes, such as the elimination of inactive neurons and
neuronal contacts. Although it is often thought that loss of
neurons or synapses is harmful, elimination of connections that do
not mediate useful information is, in fact, necessary for the
optimal signal-to-noise ratio within the nervous system.1,2 Indeed,
most of the neurons and synapses formed during development
are wiped out by adulthood.1,2 Therefore, plasticity in itself does
not have any particular direction; it is the experience-dependent
activity within the neuronal network that determines which of the
connections are strengthened and maintained and which ones are
eliminated. Therefore, plasticity is adaptive when it is guided by
beneficial environmental stimuli, but it can also be maladaptive, if
the guiding experiences are adverse.
Neuronal plasticity is heightened during critical periods of
postnatal development, which allows an efficient experience-
driven fine-tuning of developing networks.4 After the closure of
critical periods, neuronal plasticity and changes in network
structure are more restricted. However, recent data indicate that
several drugs used for the treatment of neuropsychiatric disorders
can directly influence the plasticity and reactivate a critical period-
like plasticity in the adult brain, a process known as induced
plasticity (iPlasticity).5–8
To be translated into neuronal structure and function, neuronal
activity needs molecular mediators9 and neurotrophic factors are
prime candidates for mediators between neuronal activity and
plasticity.10,11 In this review, we will first introduce the role of the
neurotrophin family and especially of BDNF as a mediator of
plasticity and drug effects. We will then discuss the role of
neuronal plasticity in the mechanisms of action of drugs acting
on the brain. Finally, we will review recent evidence that
developmental-like plasticity, iPlasticity, can be activated in the
adult brain and argue that iPlastic drugs should be combined with
training, rehabilitation or psychotherapy to facilitate treatment
outcome. For the role of other neurotrophic factors in neuronal
plasticity, especially the family members of the glial cell
line-derived neurotrophic factor, fibroblast growth factor and
insulin-like growth factor, we refer to recent review articles.12–14
NEUROTROPHINS IN PLASTICITY
The first neurotrophic factors, nerve growth factor (NGF) and
brain-derived neurotrophic factor (BDNF) were discovered
through their ability to support the survival of neurons and
neurites during development;15–17 other members of the
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neurotrophin family, neurotrophin-3 (NT-3)18–20 and neurotrophin-
4 (NT-4)21–23 were then identified through sequence similarity to
NGF and BDNF.
Neurotrophins act by binding to two types of receptors, Trk-
family members24–27 and the p75 neurotrophin receptor
(p75NTR).28–31 NGF binds to TrkA, BDNF and NT-4 to TrkB and
NT-3 interacts mainly with TrkC receptors, whereas all neurotro-
phin family members bind to the p75NTR.32 Recent evidence
suggests that mature forms of neurotrophins predominantly bind
to Trk receptors to promote neuronal survival and plasticity,
whereas intracellularly generated pro-forms of neurotrophins
preferentially interact with the p75NTR to increase cell death
and eliminate synapses.33,34
In the peripheral nervous system, neurotrophic factors are
constitutively released in minute amounts by the target cells to
regulate survival and process outgrowth of developing neurons.
To act as a mediator of activity-dependent plasticity in the central
nervous system, neurotrophins need to be released and to act in
an activity-dependent manner.10,35,36 Levi-Montalcini and co-
workers first found that hypothalamic Ngf mRNA levels in mice
were regulated by behavioral activity, namely aggression, indicat-
ing the role for neurotrophins in the regulation of behavior.37 At
the same time, Gall and co-workers showed that Ngf mRNA was
regulated by neuronal activity induced by seizures.38 A similar
activity-dependent regulation was observed for Bdnf mRNA,39–41
and subsequent studies showed that synthesis and release of
BDNF and NGF, but not those of NT-3 and NT-4, are regulated by
activity.9 Furthermore, TrkB, which is mostly localized within
vesicles inside the cell, is translocated to plasma membrane
through neuronal activity.42,43 These data are consistent with a
central role of neurotrophins as mediators of activity-dependent
plasticity9,10 (Figure 1).
The first functional evidence for the role of neurotrophins in
plasticity was obtained in the visual cortex, a classical model for
developmental plasticity, when Maffei and colleagues showed
that NGF prevents the effects of monocular deprivation (MD)
during the critical period of visual development44,45 (for a review,
see refs 46,47). These findings led the authors to propose an
influential hypothesis that thalamic axons reaching the visual
cortex compete for access to a neurotrophic factor that is
regulated by activity.44 The observation that BDNF synthesis in
the visual cortex is regulated by visual stimulation made BDNF the
prime candidate for this activity-dependent regulated factor.48
Indeed, the presence of an excess of the TrkB ligands, BDNF
and NT-4, prevented ocular column segregation during
development,49–52 which is consistent with such a role. These
studies demonstrate that neurotrophins are critical regulators of
neuronal plasticity in the developing visual cortex;53 they also
established visual cortex as an excellent model for studying the
role of neurotrophic factors in neuronal plasticity (Figure 2).
NGF and BDNF promote the outgrowth of axons and dendrites
and increase synapse formation.54–57 The effect of BDNF on
dendritic branching is dependent on neuronal activity,56 which
again is consistent with the role of BDNF in activity-dependent
plasticity.
BDNF also regulates synaptic plasticity. Long-term potentiation
(LTP) is a widely used model of synaptic plasticity and BDNF has
been demonstrated to be a critical regulator of the late, protein
synthesis-dependent stage of LTP.9,58,59 High-frequency stimula-
tion that induces LTP increases BDNF production.60,61 Further-
more, BDNF increases neurotransmitter release,62 promotes
synaptic transmission and LTP in vitro63–65 as well as in vivo.66–69
Mice deficient of BDNF fail to show LTP,70,71 which can be rescued
by exogenous BDNF administration.71–73 Similar findings have
been found in mice carrying the Val66Met mutation in the Bdnf
gene,74 which corresponds to a common human BDNF gene
polymorphism that alters the amino acid valine to methionine in
the position 66 of the BDNF pro-region, leading to impaired
activity-dependent BDNF release.75 Consistent with this, direct
current stimulation promotes learning in homozygous BDNF
Val66Val subjects, but not in Met allele carriers, both in humans
and mice.76 However, since long-term manipulations, such as
transgenic mice, can have major effects on glutamate release and
other basic synaptic properties that in turn alter the threshold for
LTP and other forms of synaptic plasticity, it is not always clear
whether the effects of neurotrophins on neuronal or synaptic
plasticity are instructive or permissive.59,77
Mice deficient in TrkB also show blunted LTP and deficient
learning.58,78 These effects appear to be specifically mediated by
signaling through the phospholipase Cγ signaling pathway, since
deletion of the tyrosine residue in TrkB mediating this signaling
disrupts LTP.79 Furthermore, overexpression of TrkB occludes LTP
in the hippocampal CA1 area, which is consistent with a critical
role for TrkB signaling in LTP.80
As noted above, plasticity is not only a trophic effect but also
includes atrophic processes such as apoptosis, axonal retraction,
dendritic pruning, synapse loss and long-term depression.
Interestingly, genes for neurotrophins produce mediators of both
of these functions. Although mature forms of neurotrophins
activate Trk family receptors to promote trophic effects, pro-forms
of neurotrophins bind to and activate the p75NTR to induce
atrophic effects.31,33,81 p75NTR is widely expressed in cortical
and hippocampal neurons during early development, but its
expression is reduced during the first postnatal weeks; however,
there is evidence that p75NTR is re-expressed in the cortex and
hippocampus after injury.31,82,83 In addition, the BDNF pro-peptide
Figure 1. Neurotrophins as regulators of activity-dependent plasti-
city. Neurotrophins and their pro-forms mediate synaptic strength-
ening and dendritic retraction, respectively. This dual action is
regulated by neuronal activity that controls the expression and
secretion of BDNF, cleavage of proBDNF and plasma membrane
translocation of TrkB receptors. BDNF binds to TrkB receptors to
mediate neuronal survival and stabilization, whereas proBDNF binds
with a higher affinity to p75NTRs that in the absence of Trk receptors
promote apoptosis, dendritic retraction and synaptic depression,
allowing differential responses in neurons depending on their
activity state. When two axons are competing for the innervation of
the same target neuron, the functional connection eventually forms
between the two active neurons and the less active neuron retracts.
Neuronal activity promotes the release of BDNF and proBDNF as
well as tPA, which promotes extracellular cleavage of proBDNF to
BDNF. In addition, TrkB receptors that normally reside inside the cell
are inserted to the plasma membrane in the active neurons. This
allows BDNF to mediate survival promoting and synapse strength-
ening signals in the active neurons. In the less active neuron, TrkB
receptors or tPA are not available; however, p75NTR is expressed
and the proBDNF released from the active neighbor or the target
cell promotes atrophic signals. These effects result in activity-
dependent selection of neuronal connectivity. BDNF, brain-derived
neurotrophic factor; ES, endoplasmic system; p75, p75 neurotrophin
receptor; proBDNF, pro-form of BDNF; tPA, tissue plasminogen
activator; TrkB, tropomyosin receptor kinase.
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that is released from pro-BDNF has recently been shown to
possess biological effects on its own.84,85 Pro-neurotrophins
induce apoptosis in the absence of Trk receptors via interaction
between sortilin and p75NTR.33,82,86,87 Pro-BDNF binding to
p75NTR has also been shown to induce pruning of axons and
dendrites85,88–91 and promote long-term depression.92–94 There is
evidence that the release of these competing signals derived from
a single pro-neurotrophin is effectively utilized by neurons
competing for target innervation to promote their own growth
while inhibiting that of competing neighbors81,95–98 (Figure 1).
NEUROTROPHINS AND PLASTICITY IN DRUG RESPONSES
Since the discovery of BDNF and its receptor TrkB, efforts have
been made to use BDNF as a therapeutic agent for neuropsychia-
tric disorders or to develop small-molecule pharmaceuticals that
could increase the production of BDNF or activate TrkB in brain
(for review, see refs 99,100), and these efforts are still ongoing.101
It is, therefore, remarkable that there actually are safe and widely
used drugs already in market that increase the production of
BDNF or the activation of TrkB in brain. In particular, the effects of
antidepressant drugs on BDNF synthesis and TrkB signaling have
been well-characterized;102–105 yet these effects have been largely
ignored by the pharmaceutical industry and clinical development.
Given the meager outcome of the efforts to develop BDNF
mimetics or TrkB agonists, one cannot escape contemplating that
many of the scientists involved in these efforts ended up being
treated with the very drugs they failed to discover.
Antidepressants activate BDNF signaling
Duman and co-workers were the first to observe that antidepres-
sant drugs acting through diverse mechanisms increased Bdnf
mRNA expression in the rat hippocampus.106 Later, multiple
studies reported that chronic antidepressant treatment increases
Bdnf mRNA expression107–109 and triggers upregulation of genes
associated with BDNF-induced plasticity.110–112 The antidep-
ressant-induced increase in Bdnf mRNA expression can be further
potentiated if the drug treatment is combined with voluntary
exercise.113 Moreover, chronic antidepressant treatment can
prevent the downregulation of Bdnf mRNA expression caused by
stress.106,109,113 In addition, BDNF protein levels as well as the
expression of genes associated with BDNF-induced plasticity are
increased after chronic antidepressant treatment.112,114 Acute
antidepressant treatment, however, does not regulate BDNF
expression.106,114–117 Studies on human subjects support the
findings in rodents; BDNF expression is increased in post-mortem
samples of the hippocampus of depressed patients on antide-
pressant medication at the time of death.118 Furthermore,
electroconvulsive shock treatment increases brain and serum
BDNF levels in rats and depressed patients, respectively.106,119
Conversely, BDNF and TrkB mRNA and protein levels are
decreased in the frontal cortex and hippocampus of suicide
victims when compared with controls.120
Genetic studies have demonstrated that BDNF signaling is
required for the behavioral effects of antidepressant drugs.105 In
BDNF heterozygous knockout mice and BDNF conditional knock-
out mice, the behavioral response to antidepressant drugs in the
Figure 2. iPlasticity in the adult visual cortex. Development of the ocular dominance (OD) and its response to monocular deprivation in the
mammalian visual cortex is probably the best-characterized model of neuronal network development in the cerebral cortex. (a) During early
life, thalamic inputs representing each eye diffusely innervate the entire visual cortex, but (b) during the CP of early postnatal life, visual inputs
from each eye segregate into alternating eye-specific regions in the primary visual cortex, called OD columns, such that each column becomes
predominant innervated by one eye only. (c) If vision of one eye is blocked (MD) during the critical period, the more active inputs of the open
eye take over the visual cortex through an activity-dependent competition involving BDNF signaling, and the closed eye loses its connectivity
(see Figure 1), thereby becoming poor in vision, or amblyopic. Vision of the amblyopic eye can be recovered if normal vision is restored during
the critical period and the use of the weaker eye is encouraged by patching the better eye, but if MD extends beyond the end of the critical
period, amblyopia becomes permanent and cannot be revised by patching. (d) However, vision of an amblyopic eye can be restored in
adulthood if eye patching is combined with a treatment that induces iPlasticity, such as fluoxetine or environmental enrichment (see Table 1).
iPlasticity promotes functional recovery also in other brain areas where abnormal environment has lead to miswiring of developing networks.
Modified with permission from Elsevier Ltd from Castrén and Hen.3 BDNF, brain-derived neurotrophic factor; CP, critical period; MD, monocular
deprivation.
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forced swim test is abolished.105,115,121 Moreover, after chronic
mild stress, BDNF heterozygous knockout mice did not respond to
chronic imipramine treatment in the novelty suppressed feeding
test.122 On the other hand, administration of BDNF directly into
the midbrain region123 or hippocampus is sufficient to induce
antidepressant-like behavior and neurogenesis.69,124
The increase in BDNF expression takes several days of
antidepressant treatment to develop, but a single acute admin-
istration of many different antidepressants rapidly increases the
phosphorylation of TrkB.115–117 This delayed increase in BDNF
expression may be mediated by TrkB activation, since BDNF is
known to regulate its own expression through TrkB.125,126
Antidepressants increase TrkB phosphorylation at the phospholi-
pase Cγ-binding site (Y816), but not at the Shc-binding tyrosine
(Y515) and the phosphorylation takes place independent of
BDNF,117 indicating TrkB transactivation. Interestingly, fluoxetine
activates TrkB receptor similarly in wild-type mice and mice
lacking the serotonin transporter, the main target of fluoxetine.117
TrkB receptor overexpression, which results in increased TrkB
signaling, is sufficient to produce antidepressant-like behavioral
effect in the forced swim test.127 Intact TrkB signaling is required
for the behavioral effects of antidepressant drugs, since mice
overexpressing the dominant-negative truncated form of the TrkB
receptor do not respond to antidepressant drugs in the forced
swim test.115 Moreover, the behavioral effects of chronic
antidepressant treatment were blunted in mice lacking TrkB in
the newly born hippocampal neurons.128 In addition to activating
TrkB receptor signaling, chronic treatment with antidepressant
drugs increases Trkb mRNA expression.106
Chronic stress is an important precipitating factor for depres-
sion and has been shown to induce atrophic changes in dendritic
complexity and thus affect neuronal network function. Interest-
ingly in animal models, antidepressant treatment during the
chronic stress paradigm can counteract the effects of stress on
dendritic spines via a mechanism that includes regulation of
glucocorticoid receptor phosphorylation by BDNF.129 Specifically,
BDNF through TrkB activation regulates the functional conse-
quences of the glucocorticoid receptor activation following
stress.130
Taken together, these data convincingly demonstrate that
antidepressant drugs activate TrkB signaling and subsequently
increase BDNF levels in brain, and that BDNF signaling is critical for
the behavioral effects of antidepressants. Therefore, effective TrkB
agonists exist and are therapeutically used by millions of patients.
Antidepressants and neuronal plasticity
The finding that BDNF expression is increased by antidepressants
was the trigger for the hypothesis that neuronal plasticity is
involved in the antidepressant drug action.102 Since then, several
lines of data indicate that antidepressant drugs activate and act
through neuronal plasticity.3 Neurogenesis in adult animals is
restricted to the subventricular zone of lateral ventricles and to the
dentate gyrus of the hippocampus.131 Hippocampal neurogenesis
is sensitive to a variety of environmental stimuli, including
exercise, enrichment and antidepressant treatment.131 Essentially
all antidepressant drugs increase hippocampal neurogenesis after
~ 2 weeks of treatment in rodents132–135 and neurogenesis
appears to be required for many, although not all the behavioral
effects of antidepressant drugs.133,136,137 The effects of antide-
pressants on neurogenesis are dependent on the intact BDNF
signaling through TrkB.128,138
In addition to hippocampal neurogenesis, antidepre-
ssants increase remodeling of axons and dendrites in the
hippocampus110,139 as well as in the prefrontal cortex.137
Antidepressants also increase synaptogenesis apparently by
increasing spine turnover.137,140,141 Furthermore, antidepressants
promote LTP in the hippocampus, cortex and amygdala5,139,142,143
and propagation of signals through hippocampal circuitry.144,145
Although the effects of antidepressants on dendritic remodeling
in the dentate gyrus are associated with ongoing neurogenesis,139
in other parts of the hippocampus and in the prefrontal cortex
these effects are independent of neurogenesis.137
Ketamine
Ketamine has recently received a lot of attention as a rapid-acting
antidepressant drug146 (for a review, see ref. 147). A single dose of
ketamine alleviates depression within an hour, but the effect lasts
for a week or more, even though the half-life of ketamine and its
metabolites is only a few hours.146,147 This temporal discrepancy
between the effects and kinetics of ketamine suggests that
neuronal plasticity may be behind the long-lasting effects.148
Indeed, ketamine promotes synaptogenesis in the rodent
prefrontal cortex.148,149 Ketamine has also been reported to
promote hippocampal neurogenesis,150,151 but neurogenesis
does not appear to be necessary for the antidepressant effects
of this drug.151
BDNF and TrkB have been linked to the mechanism of the
antidepressant actions of ketamine.103,148 BDNF Val66Met poly-
morphism can affect the responsiveness to ketamine in humans
and rodents. The ability of ketamine to induce dendritic spine
formation was abolished in BDNF Met66Met mice and the mice
failed to respond to ketamine in FST.152 Depressed human
patients carrying the met allele did not respond to ketamine as
effectively as the Val66Val carriers.153 These results suggest that
the activity-dependent secretion, which is impaired in BDNF Met
carriers, is involved in the mechanism of ketamine action. In
cultured neurons, ketamine stimulation indeed increases BDNF
secretion.154
The ketamine metabolite, (2R,6R)-hydroxynorketamine (HNK),
can reproduce the behavioral effects of ketamine in animal
models,155 although it does not bind to NMDA receptors that are
thought to be the main targets mediating the effects of ketamine.
Instead, (2R,6R)-HNK increases AMPA-mediated currents and BDNF
expression. The NMDA receptor-independent actions of (2R,6R)-
HNK suggest that mechanisms other than NMDA antagonism,
such as the effects mediated by BDNF and TrkB, can be crucial in
the antidepressant effects of ketamine. This hypothesis is
supported by findings from Autry et al.156 that a single ketamine
injection rapidly increases the TrkB receptor activation and the
translation of BDNF via eukaryotic elongation factor 2 in the
mouse hippocampus, effects that are also seen after chronic
fluoxetine treatment.157 Furthermore, the antidepressant-like
behavioral effects of ketamine were lost in mice lacking BDNF or
TrkB or if BDNF function blocking antibody was infused into the
medial prefrontal cortex of rats.154,156 In BDNF heterozygous
knockout mice, however, the response to ketamine in FST is
preserved, suggesting that ketamine is able to produce anti-
depressant effects in situations where BDNF expression is reduced
but not completely lost.158
Fingolimod
Fingolimod is a sphingosine-1-phosphate receptor modulator that
is clinically used for multiple sclerosis, but it has been suggested
for the treatment of several neurological disorders, including
Huntington’s disease and Rett syndrome, where BDNF signaling
has been implicated.159 Indeed, fingolimod increases BDNF levels
in cultured neurons and in brain and rescues reduced BDNF levels
in the brain of Rett syndrome model mice.160 In addition,
fingolimod has been shown to improve memory and prevent
the upregulation of p75NTR in Huntington’s disease model
mice.161 Finally, fingolimod has antidepressant-like effects,162
which is consistent with the critical role of BDNF signaling in the
antidepressant drug action.
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Drug-induced Trk receptor transactivation
TrkB receptors can be activated independently of BDNF via
transactivation through other receptors. TrkB receptor appears to
mediate, in particular, the neuronal survival promoting effects of
compounds able to transactivate TrkB.163 For example, the
adenosine A2 and PACAP receptors that belong to the family of
G-protein-coupled receptors can transactivate Trk receptors.164,165
In vivo, the effects of adenosine 2 A receptor agonists on
survival of motoneurons were mediated via TrkB receptor
transactivation.166 In addition to transactivation via G-protein-
coupled receptors, TrkB receptor activation and signaling can be
induced by glucocorticoids, for example dexamethasone, to
mediate their effects on neuronal survival.167
Drugs of abuse
Drugs of abuse produce long-lasting memories, typically persist-
ing for life and neuronal plasticity has been for a long time
implicated in the formation and maintenance of these memories
(for a thorough discussion of this area, see refs 168–170). The first
evidence for long-term plastic changes in response to an addictive
drug was observed in the dopaminergic neurons originating from
the ventral tegmental area and forming synapses in the nucleus
accumbens (NAc). A single cocaine administration induced an LTP
in this synapse that was observed 24 h after the cocaine
administration but no longer at 1 week after.171 Repeated cocaine
injections also induce production of new synapses in the
excitatory projections to NAc, which remain silent expressing
only NMDA receptors and having no AMPA-receptor mediated
currents.172 Subsequently, during withdrawal, AMPA-receptors are
gradually recruited to these silent synapses, which converts them
to mature synaptic contacts.173
The role of neurotrophins in addiction has been extensively
studied, particularly by Nestler and co-workers.174 BDNF is
expressed in dopamine neurons as well as in excitatory neurons
projecting to the NAc and TrkB is expressed in both dopamine D1
and D2 receptor expressing neurons in the NAc.174,175 Expression
of both BDNF and TrkB is increased by cocaine exposure176,177 and
inhibition of BDNF-TrkB signaling reduces the rewarding effects of
cocaine.177 Interestingly, TrkB signaling within the D2-expressing
NAc neurons promotes reward to cocaine, whereas TrkB in the D1
neurons suppresses it.175 In contrast, chronic morphine adminis-
tration reduces BDNF expression in the ventral tegmental area and
suppression of BDNF signaling in the NAc promotes morphine
reward.178 Therefore, BDNF as well as other neurotrophic factors
(for a review of the role of glial cell line-derived neurotrophic
factor, see ref. 179) have a critical, though complex, role in the
neuronal plasticity leading to addiction.
It has been proposed that addictive drugs of abuse 'hijack' a
process of neuronal plasticity that normally takes place during
development. Nestler and co-workers have proposed a neural
rejuvenation hypothesis of addiction, which suggests that
repeated exposure to cocaine reactivates developmental pro-
cesses that normally occur in the juvenile brain.170 It will be
important to explore whether rejuvenation and iPlasticity in fact
represent a common mechanism through which developmental
plasticity is activated in the adult brain through drugs or
experiences to promote adaptive or maladaptive plasticity.
ROLE OF IPLASTICITY IN DRUG RESPONSES
Plasticity is adaptation of the nervous system to environmental
experiences, and since exposure to a drug is an experience, it is to
be expected that drugs acting on the nervous system involve
plasticity. However, recent evidence suggests that central
processes of developmental plasticity, such as critical periods,
neurogenesis and synaptic plasticity, can be direct targets of drug
treatments.
Postnatal critical or sensitive periods are phases of heightened
neuronal plasticity during which a certain network is particularly
sensitive to environmental input and experiences have a large
impact on the subsequent structure and function of the network.4
A classical experimental set-up for the investigation of critical
periods is the development of the mammalian visual cortex4,180
(Figure 2). In this process a perfectly healthy eye that has grown its
projections to the visual cortex normally, may lose its connectivity
and become permanently deficient only because it is deprived of
activation during the critical period. Critical periods are ubiquitous
and also govern the development of, for example, motor learning,
language and social interactions.181–183 Therefore, abnormal
experiences during early life can guide maladaptive wiring of
many cortical networks, including those governing social interac-
tions, and this wiring becomes permanent after the closure of the
corresponding critical period, impeding normal adaptation of the
network function. Critical periods typically have a relatively well-
defined boundaries and it is known that GABA-mediated signaling
as well as BDNF are central regulators of the opening and closure
of these boundaries.4,184,185 Drugs acting on GABA receptors, such
as benzodiazepines and anesthetics, are occasionally used in
children and adolescents, but so far very little is known about the
impact of these drug treatments on the opening and closure of
critical periods, a field that clearly would benefit from more
attention.
iPlasticity: induced critical period-like plasticity in the adult brain
It had been considered that once closed, critical periods remain
closed. However, recent evidence has demonstrated that it is
possible to reactivate a state of plasticity in the adult cerebral
cortex closely resembling that observed at the peak of postnatal
critical periods.3,7,104,186 This iPlasticity creates a window of
opportunity for better rewiring of abnormally connected or
injured neuronal networks, which has obvious potential in the
treatment of neuronal trauma and psychiatric disorders (Figure 2).
Furthermore, since natural critical periods coincide with a period
of brain growth when many experimental procedures such as
brain imaging are complicated, iPlasticity that can be induced in
the adult brain facilitates investigations of the molecular and
cellular mechanisms of enhanced plasticity.
The first chemical treatment that was shown to induce critical
period-like plasticity in the adult brain was the enzyme
chondroitinase ABC (ChABC) that, upon intracerebral infusion,
degrades perineuronal nets, extracellular matrix structures pre-
ferentially encasing parvalbumin-expressing interneurons.187
Table 1. iPlastic drugs
Drug Administration Assay Species Role of BDNF Ref
Chondroitinase Intracortical VC R ? 188
FC M ? 190
Intrathecal SC R ? 189
Fluoxetine p.o. VC R, M + 5,141
FC M + 143
DG M ? 6
SC R ? 191
AChEI VC M ? 192
HDACI i.p. VC R ? 193–195
i.p. AC M ? 196
p.o. AC H ? 197
IGF-1 Intracortical VC R ? 198
Abbreviations: AC, auditory cortex; AChEI, acetylcholinesterase inhibitor;
BDNF, brain-derived neurotrophic factor; DG, dentate gyrus; FC, fear
conditioning, H, human; HDACI, histone deacetylase inhibitor; IGF-1,
insulin-like growth factor-1; i.p., intraperitoneal; M, mouse; p.o., peroral;
R, rat; SC spinal cord lesion; VC, visual cortex.
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Intracerebral infusion of ChABC was shown to reactivate a critical
period-like ocular dominance (OD) plasticity after MD in the rat
visual cortex.188 Degradation of perineuronal nets has been shown
to reactivate early life-like plasticity also in the spinal cord and fear
circuitry.189,190 Subsequently, several pharmacological treatments
(Table 1) and environmental manipulations,7,199–201 as well as
genetic means, have been used to induce iPlasticity in several
model systems and also in humans.186 Clearly, iPlasticity is an
increasingly recognized pharmacological principle with a wide
range of potential applications.
iPlasticity induced by antidepressant drugs
Intracortical infusion of ChABC is an invasive procedure and not
feasible for human use. However, recent findings have shown that
the antidepressant fluoxetine activates iPlasticity in the adult rat
visual cortex in a manner very similar to that found at the peak of
the natural critical period and to that produced by ChABC or
enriched environment.5,104,141 During chronic treatment by
fluoxetine, critical period-like plasticity is reactivated and MD
induces a shift in OD in the visual cortex of adult rats5 (Figure 2).
Further, in rats rendered amblyopic through MD from early life
onwards, opening of the weak eye and patching of the healthy
eye in adulthood restores vision to the amblyopic eye only when
fluoxetine is given during the patching procedure.5 BDNF levels
are increased by fluoxetine in the visual cortex and BDNF signaling
through TrkB is required for iPlasticity. Furthermore, fluoxetine
reduces intracortical inhibition and diazepam that potentiates
GABA-mediated inhibition, prevents its effects on visual plasticity.5
Finally, serotonin through 5HT1A receptors is involved in
iPlasticity.193 Fluoxetine has also been shown to produce
enhanced structural plasticity in the mouse visual cortex,
promoting turnover of synaptic sites.141 Essentially all antidepres-
sant drugs increase TrkB signaling in brain,116 but it is not clear
whether iPlasticity is produced by other antidepressants than
fluoxetine. However, preliminary data show that tianeptine, an
antidepressant that does not inhibit monoamine reuptake,202
readily reactivates OD plasticity in the adult rat visual cortex (JF
Maya-Vetencourt, A Cattaneo and E Castrén, unpublished), which
suggests that iPlasticity might be induced by other antidepressant
drugs as well. It should be emphasized that fluoxetine treatment
alone has no effects on the vision in rats; the effects on visual
acuity only become apparent when the promoted plasticity is
combined with a manipulation (such as MD) that produces a new
pattern of activity within the plastic networks.5
iPlasticity produced by fluoxetine is not restricted to the visual
cortex. Chronic peroral fluoxetine exposure induces markers of
critical period-like plasticity and promotes LTP in the amygdala,
which is indicative of iPlasticity.143,203 These effects also reactivate
the ability to suppress fearful memories when fluoxetine
treatment is combined with extinction training.143 Similar iPlastic
effects have also been shown after injection of ChABC into the
amygdala in adult mice.190 As was the case for iPlasticity in the
visual cortex, the effects of fluoxetine on fear extinction were also
dependent on BDNF signaling and were apparent only when
fluoxetine treatment was combined with rehabilitation, in this
case extinction training.143 Taken together, iPlasticity may
constitute a neurobiological basis for the observation that the
combination of antidepressant treatment and psychotherapy
works better than either treatment alone.143
In the adult hippocampal dentate gyrus, fluoxetine reverts the
molecular and functional properties of granule neurons to an
immature state, a phenomenon coined dematuration.6,204
Although dematuration coincides with iPlasticity in other cortical
regions, it is currently unclear whether these two phenomena
share the same molecular and cellular background.
Fluoxetine has recently been found to promote recovery from
stroke and from brain trauma.205–207 It is possible that iPlasticity
has a significant role in these actions. In rats, iPlasticity induced
either by ChABC or fluoxetine improves recovery from spinal cord
lesion.189,191 If iPlasticity was the underlying mechanism, fluox-
etine (promoting plasticity) and rehabilitation (guiding plasticity
by activity) together should produce an even better response than
either treatment alone; this should be taken into consideration in
patient care and in the design of future clinical trials.
Taken together, these data demonstrate that a safe and widely
used drug fluoxetine can reactivate critical period-like plasticity in
many cortical regions and promote recovery of vision in an
amblyopic eye in adult rodents, but whether similar effects are
produced in humans is not clear. Normann and co-workers
showed that a 3-week treatment with the antidepressant sertra-
line increases visually evoked potentials in response to a strong
visual stimulation in healthy humans,208 which is reminiscent of
the increased LTP produced by fluoxetine in rats,5 indicating that
antidepressants influence human visual cortex. However, in a
recent clinical trial in amblyopic patients, fluoxetine and placebo
were equally effective in improving the acuity of the amblyopic
eye when given together with a daily eye patching and a computer
game-based training of the weaker eye (H Huttunen, M Palva,
L Lindberg, S Palva, V Saarela, J Liinamaa, E Karvonen, M-L Latvala,
S Booms, E Castrén and H Uusitalo, unpublished observations).
Therefore, it remains unclear to what extent iPlasticity contributes
to the clinical effects of antidepressant drugs in humans.
iPlasticity induced by other drug treatments
Experiences have long-lasting effects on gene expression through
the epigenetic regulation of chromatin structure and DNA
methylation.209,210 Histone acetylation is one of the key epigenetic
mechanisms promoting the open chromatin state and regulating
gene expression. Histone acetylation can be increased by
inhibitors of histone deacetylase (HDAC) and several drugs in
clinical use act as HDAC inhibitors.209 Since activity-dependent
plasticity requires changes in gene expression and protein
synthesis, HDAC inhibitors might activate iPlasticity. Indeed, HDAC
inhibition increases the expression of plasticity-related factors and
promotes OD plasticity in the visual cortex.193–195 Treatment with
the HDAC inhibitor valproate also reactivates the plasticity related
to music preference in mice through activation of plasticity in a
network including the prefrontal cortex.196 Interestingly, valproate
promotes auditory pitch recognition in human volunteers;197 since
development of perfect pitch has a postnatal critical period, this
finding is consistent with valproate-activated iPlasticity in the
auditory pitch circuitry in humans.
Cholinergic innervation has been known for a long time to
regulate critical period plasticity.211 The cholinesterase inhibitor
physostigmine was recently demonstrated to induce OD plasticity
in the adult mouse visual cortex and to reverse amblyopia in
adulthood when given together with patching of the better
eye,192 suggesting that cholinesterase inhibitors induce iPlasticity.
Since physostigmine has side effects, it would be important to
investigate whether other cholinesterase inhibitors with fewer
side effects, such as donepezil, which is widely used for dementia,
also activate iPlasticity. Indeed, a clinical trial is ongoing to test
whether donepezil together with patching of the better eye can
be used for the treatment of residual amblyopia after the closure
of the natural critical period in humans (https://clinicaltrials.gov/
ct2/show/NCT01584076).
Finally, it should be kept in mind that iPlasticity can also be
achieved in the visual cortex with purely environmental
manipulations, such as environmental enrichment or food
restriction.7,199–201 iPlasticity induced by fluoxetine and enriched
environment closely resemble each other and they both share
electrophysiological properties with the naturally occurring critical
period. iPlasticity induced by cortical injection of IGF-1 was
occluded by the simultaneous exposure to enriched environment;
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one explanation of this finding is that both treatments share the
same core mechanisms.198 However, iPlasticity induced by calorie
restriction is not dependent on BDNF.201 Plasticity induced by
transcranial magnetic stimulation is more pronounced in BDNF
Val66Val subjects than in Met allele carriers, suggesting that
iPlasticity may also be involved in the TMS-induced plasticity.212
Clearly, more information is needed about the cellular and
molecular mechanisms that govern iPlasticity and to which extent
these mechanisms recapitulate those in play during the natural
critical periods. Nevertheless, the fact that critical periods are
ubiquitous suggests that iPlasticity could be beneficial in the
treatment of many neurological and psychiatric disorders,
especially when combined with rehabilitation.104
CONCLUSIONS
Neurotrophins are regulated by several classes of drugs used in
clinical practice. Many of these drugs also induce iPlasticity, a
newly recognized pharmacological principle where drugs can be
used to directly promote neuronal plasticity. If iPlasticity is
induced by drugs that are consumed by millions of people, why
has it not been recognized before? One possibility is that
iPlasticity is a central mechanism producing the expected clinical
effects these drugs, such as mood recovery in the case of
antidepressants.104 The disorders being treated by iPlastic drugs,
such as depression, may also themselves restrict neuronal
plasticity and thereby limit the observable plastic effects. Another
potential reason is that although iPlasticity has now been
recognized in several species of experimental animals, iPlasticity
may not take place in the human brain. Finally, it must be
emphasized that iPlastic drugs need to be combined with
rehabilitation to guide the plastic networks towards a new
function. Such rehabilitation may not be a prominent component
of current treatment strategies, but with the advent of smart
phones and virtual reality, it is possible to design novel and
inexpensive rehabilitation programs that combined with iPlasticity
may significantly potentiate the effects of currently available drugs.
Such combinations of iPlasticity and rehabilitation could also extend
the utility of available drugs into new clinical indications and might
have a significant impact on the recovery from, for example,
neurological insults. There is already evidence for this.207
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